Dana-farber-cancer Institute Inc.

F Stephen Hodi

Glenn Dranoff

Kai W Wucherpfennig

Christopher Harvey

Bettina Franz

Kenneth F May, Jr

Xinqi Wu

Jingjing Li

Gordon James Freeman

Joseph A Mollick

Kenneth May

Jan Schmollinger

Jun Zhou

The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.

Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms

The present invention is based on the identification of novel biomarkers predictive of responsiveness to a combination of anti-immune checkpoint and anti-angiogenesis therapies.

Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses

The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.

Therapeutic peptides

The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.

Vaccine compositions and methods for restoring NKG2D pathway function against cancers

The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).

Antibodies that bind to MHC class I polypeptide-related sequence A

The present disclosure provides, in part, compositions comprising an antibody or antibody fragment that immunospecifically binds to MCH class I polypeptide-related sequence A (MICA), or an epitope thereof.

The invention features tumor antigens; tumor antigen-encoding nucleic acids; antibodies specific for tumor antigens and methods of using the antibodies; methods of identifying tumor antigens and the nucleic acids that encode them; methods of monitoring or diagnosing tumors in patients; methods of testing patients for the increased likelihood of developing a tumor; and methods and compositions for treatment of a tumor or prophylaxis against developing a tumor.

Growing community of inventors

Framingham, MA, United States of America

F Stephen Hodi